PURPOSE: To investigate the results of treatment for adult patients with Burkitt's and Burkitt-like non-Hodgkin's lymphoma (NHL) undergoing high-dose therapy and autologous stem-cell transplantation (ASCT), and to determine prognostic factors for this group. PATIENTS AND METHODS: A retrospective analysis of 117 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between June 1984 and November 1994. Seventy of these patients received high-dose therapy and stem-cell transplantation in first complete remission (CR). Data on all patients were reviewed, and prognostic factors were determined by univariate and multivariate analysis. RESULTS: The actuarial overall survival (OS) rate for the entire group was 53% at 3 years. The major factor predicting for outcome after transplantation was disease status: the 3-year actuarial OS rate was 72% for patients transplanted in first CR, compared with 37% for patients in chemosensitive relapse, and 7% for chemoresistant patients. For patients transplanted in first CR, disease bulk at the time of ASCT was the only factor predictive of progression-free survival (PFS) and OS. CONCLUSION: The results of high-dose therapy and ASCT for patients with relapsed disease, particularly chemosensitive relapse, are superior to those reported for conventional-dose salvage regimens. The results for patients transplanted in first CR require comparison with modern dose-intensive regimens.
PURPOSE: To investigate the results of treatment for adult patients with Burkitt's and Burkitt-like non-Hodgkin's lymphoma (NHL) undergoing high-dose therapy and autologous stem-cell transplantation (ASCT), and to determine prognostic factors for this group. PATIENTS AND METHODS: A retrospective analysis of 117 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between June 1984 and November 1994. Seventy of these patients received high-dose therapy and stem-cell transplantation in first complete remission (CR). Data on all patients were reviewed, and prognostic factors were determined by univariate and multivariate analysis. RESULTS: The actuarial overall survival (OS) rate for the entire group was 53% at 3 years. The major factor predicting for outcome after transplantation was disease status: the 3-year actuarial OS rate was 72% for patients transplanted in first CR, compared with 37% for patients in chemosensitive relapse, and 7% for chemoresistant patients. For patients transplanted in first CR, disease bulk at the time of ASCT was the only factor predictive of progression-free survival (PFS) and OS. CONCLUSION: The results of high-dose therapy and ASCT for patients with relapsed disease, particularly chemosensitive relapse, are superior to those reported for conventional-dose salvage regimens. The results for patients transplanted in first CR require comparison with modern dose-intensive regimens.
Authors: Maria Joosten; Sebastian Ginzel; Christian Blex; Dmitri Schmidt; Michael Gombert; Cai Chen; René Martin Linka; Olivia Gräbner; Anika Hain; Burkhard Hirsch; Anke Sommerfeld; Anke Seegebarth; Uschi Gruber; Corinna Maneck; Langhui Zhang; Katharina Stenin; Henrik Dieks; Michael Sefkow; Carsten Münk; Claudia D Baldus; Ralf Thiele; Arndt Borkhardt; Michael Hummel; Hubert Köster; Ute Fischer; Mathias Dreger; Volkhard Seitz Journal: Mol Oncol Date: 2016-06-09 Impact factor: 6.603
Authors: Nicholas J Short; Hagop M Kantarjian; Heidi Ko; Joseph D Khoury; Farhad Ravandi; Deborah A Thomas; Guillermo Garcia-Manero; Maria Khouri; Jorge E Cortes; William G Wierda; Srdan Verstovsek; Zeev Estrov; Alessandra Ferrajoli; Philip A Thompson; Sherry Pierce; Susan M O'Brien; Elias Jabbour Journal: Am J Hematol Date: 2017-04-18 Impact factor: 10.047
Authors: Leena V Maramattom; Parameswaran N Hari; Linda J Burns; Jeanette Carreras; William Arcese; Mitchell S Cairo; Luciano J Costa; Timothy S Fenske; Michael Lill; Cesar O Freytes; Robert Peter Gale; Thomas G Gross; Gregory A Hale; Mehdi Hamadani; Leona A Holmberg; Jack W Hsu; David J Inwards; Hillard M Lazarus; David I Marks; David G Maloney; Richard T Maziarz; Silvia Montoto; David A Rizzieri; Baldeep Wirk; James L Gajewski Journal: Biol Blood Marrow Transplant Date: 2012-11-27 Impact factor: 5.742
Authors: Kylie D Mason; Cassandra J Vandenberg; Clare L Scott; Andrew H Wei; Suzanne Cory; David C S Huang; Andrew W Roberts Journal: Proc Natl Acad Sci U S A Date: 2008-11-11 Impact factor: 11.205
Authors: Katharina Kriegsmann; Petra Pavel; Tilmann Bochtler; Anita Schmitt; Sandra Sauer; Mark Kriegsmann; Thomas Bruckner; Stefan Klein; Harald Klüter; Carsten Müller-Tidow; Patrick Wuchter Journal: Transfus Med Hemother Date: 2020-09-15 Impact factor: 3.747